Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02354625 · ClinicalTrials.gov registry record · Phase 1
The Safety of ahSC in Chronic SCI With Rehabilitation
A Phase 1 study, sponsored by W. Dalton Dietrich.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02354625: Completed Phase 1 study, sponsored by W. Dalton Dietrich.
NCT02354625 is a Phase 1 study that has completed, run by W. Dalton Dietrich. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02354625, a Phase 1 study, has completed, sponsored by W. Dalton Dietrich.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety of autologous human Schwann cell (ahSC) transplantation in participants with chronic SCI. This trial design is phase I, open label, unblinded, non-randomized, and non-placebo controlled multiple injury cohorts.
Interventions
- BIOLOGICAL Autologous human Schwann cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-01 |
| Est. Completion | 2019-08-12 |
| Phase | Phase 1 |
What the finished NCT02354625 record still lists
NCT02354625 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which Autologous human Schwann cells is the first listed.
NCT02354625 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02354625 about?
NCT02354625 is a clinical study titled "The Safety of ahSC in Chronic SCI With Rehabilitation". The purpose of this study is to assess the safety of autologous human Schwann cell (ahSC) transplantation in participants with chronic SCI. This trial design is phase I, open label, unblinded, non-randomized, and non-placebo controlled multiple injury cohorts.
What is the current status of trial NCT02354625?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-01. Estimated completion is 2019-08-12.
What interventions are being tested in trial NCT02354625?
The interventions under investigation include: Autologous human Schwann cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02354625?
This trial is sponsored by W. Dalton Dietrich, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02354625's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia